Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Morgan Healthcare Conference in San Francisco. Promising efficacy signals for ORIC-944 in metastatic castration-resistant prostate cancer and a collaboration evaluating enozertinib with Johnson & Johnson's amivantamab have strengthened confidence in the company's late-stage cancer pipeline. We'll now examine how this combination of encouraging ORIC-944 data and heightened analyst attention shapes ORIC Pharmaceuticals' broader investment narrative. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit For ORIC Pharmaceuticals, the investment case still rests on whether its late-stage oncology programs can eventually justify years of losses and ongoing dilution. The latest J.P. Morgan conference appearance, alongside fresh ORIC-944 combination data and the new enozertinib collaboration with Johnson & Johnson, reinforces that the near-term story is all about clinical catalysts rather than revenue or earnings. With
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Catalyst Watch: Intel earnings, drama in Davos, and the fight for Warner Bros. [Seeking Alpha]Seeking Alpha
- Big pharma and investors re-engage in CGTs and race to scale [Yahoo! Finance]Yahoo! Finance
- 2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income [Yahoo! Finance]Yahoo! Finance
- TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide [Yahoo! Finance]Yahoo! Finance
- TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomidePR Newswire
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website